{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T06:36:13Z","timestamp":1791873373448,"version":"4.3.4"},"reference-count":39,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,24]],"date-time":"2025-03-24T00:00:00Z","timestamp":1742774400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lipidjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.jacl.2025.03.014","type":"journal-article","created":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T10:35:44Z","timestamp":1743158144000},"page":"468-476","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Triglyceride-rich lipoprotein sphingolipids are altered in primary hypertension: A pilot case-control study"],"prefix":"10.1016","volume":"19","author":[{"given":"Fazil M.","family":"Alidjan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9209-4029","authenticated-orcid":false,"given":"Sandra den","family":"Hoedt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mardin","family":"Rashid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonie C. van der","family":"Zee-van Vark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gardi J.","family":"Voortman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristien Y.","family":"Dorst-Lagerwerf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Christoffersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melvin","family":"Lafeber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6870-9962","authenticated-orcid":false,"given":"Jeanine E.","family":"Roeters van Lennep","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6767-4208","authenticated-orcid":false,"given":"Adrie J.M.","family":"Verhoeven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7743-1907","authenticated-orcid":false,"given":"Edith C.H.","family":"Friesema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monique T.","family":"Mulder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.jacl.2025.03.014_bib0001","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/s41569-021-00536-1","article-title":"Ceramides and other sphingolipids as drivers of cardiovascular disease","volume":"18","author":"Choi","year":"2021","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.jacl.2025.03.014_bib0002","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.915961","article-title":"Sphingolipid metabolism and signaling in cardiovascular diseases","volume":"9","author":"Borodzicz-Jazdzyk","year":"2022","journal-title":"Front Cardiovasc Med"},{"issue":"5","key":"10.1016\/j.jacl.2025.03.014_bib0003","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1161\/HYPERTENSIONAHA.119.14507","article-title":"Endothelial sphingolipid De novo synthesis controls blood pressure by regulating signal transduction and NO via ceramide","volume":"75","author":"Cantalupo","year":"2020","journal-title":"Hypertension"},{"issue":"7","key":"10.1016\/j.jacl.2025.03.014_bib0004","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0021817","article-title":"Hypertension is associated with marked alterations in sphingolipid biology: a potential role for ceramide","volume":"6","author":"Spijkers","year":"2011","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.jacl.2025.03.014_bib0005","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1161\/HYPERTENSIONAHA.117.09088","article-title":"S1PR1 (Sphingosine-1-Phosphate Receptor 1) signaling regulates blood flow and pressure","volume":"70","author":"Cantalupo","year":"2017","journal-title":"Hypertension"},{"issue":"12","key":"10.1016\/j.jacl.2025.03.014_bib0006","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0052985","article-title":"The clinically-tested S1P receptor agonists, FTY720 and BAF312, demonstrate subtype-specific bradycardia (S1P(1)) and hypertension (S1P(3)) in rat","volume":"7","author":"Fryer","year":"2012","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.jacl.2025.03.014_bib0007","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1161\/HYPERTENSIONAHA.120.17379","article-title":"Plasma S1P (sphingosine-1-phosphate) links to hypertension and biomarkers of inflammation and cardiovascular disease: findings from a translational investigation","volume":"78","author":"Jujic","year":"2021","journal-title":"Hypertension."},{"key":"10.1016\/j.jacl.2025.03.014_bib0008","doi-asserted-by":"crossref","DOI":"10.1038\/srep44131","article-title":"Vascular transcriptome profiling identifies sphingosine kinase 1 as a modulator of angiotensin II-induced vascular dysfunction","volume":"7","author":"Siedlinski","year":"2017","journal-title":"Sci Rep"},{"issue":"10","key":"10.1016\/j.jacl.2025.03.014_bib0009","doi-asserted-by":"crossref","first-page":"3074","DOI":"10.1194\/jlr.D008532","article-title":"Blood sphingolipidomics in healthy humans: impact of sample collection methodology","volume":"51","author":"Hammad","year":"2010","journal-title":"J Lipid Res"},{"issue":"8","key":"10.1016\/j.jacl.2025.03.014_bib0010","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1194\/jlr.M600055-JLR200","article-title":"Isolation and characterization of human apolipoprotein M-containing lipoproteins","volume":"47","author":"Christoffersen","year":"2006","journal-title":"J Lipid Res"},{"issue":"389","key":"10.1016\/j.jacl.2025.03.014_bib0011","doi-asserted-by":"crossref","first-page":"ra79","DOI":"10.1126\/scisignal.aaa2581","article-title":"HDL-bound sphingosine 1-phosphate acts as a biased agonist for the endothelial cell receptor S1P1 to limit vascular inflammation","volume":"8","author":"Galvani","year":"2015","journal-title":"Sci Signal"},{"issue":"1","key":"10.1016\/j.jacl.2025.03.014_bib0012","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1159\/000362993","article-title":"HDL-bound sphingosine 1-phosphate (S1P) predicts the severity of coronary artery atherosclerosis","volume":"34","author":"Sattler","year":"2014","journal-title":"Cell Physiol Biochem"},{"issue":"4","key":"10.1016\/j.jacl.2025.03.014_bib0013","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1172\/JCI200418004","article-title":"HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3","volume":"113","author":"Nofer","year":"2004","journal-title":"J Clin Invest"},{"issue":"2","key":"10.1016\/j.jacl.2025.03.014_bib0014","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1093\/cvr\/cvp024","article-title":"Native and reconstituted HDL activate Stat3 in ventricular cardiomyocytes via ERK1\/2: role of sphingosine-1-phosphate","volume":"82","author":"Frias","year":"2009","journal-title":"Cardiovasc Res"},{"issue":"25","key":"10.1016\/j.jacl.2025.03.014_bib0015","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1093\/eurheartj\/ehw148","article-title":"Plasma ceramides predict cardiovascular death in patients with stable coronary artery disease and acute coronary syndromes beyond LDL-cholesterol","volume":"37","author":"Laaksonen","year":"2016","journal-title":"Eur Heart J"},{"issue":"9","key":"10.1016\/j.jacl.2025.03.014_bib0016","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1194\/jlr.P081281","article-title":"Plasma concentrations of molecular lipid species predict long-term clinical outcome in coronary artery disease patients","volume":"59","author":"Anroedh","year":"2018","journal-title":"J Lipid Res"},{"issue":"7","key":"10.1016\/j.jacl.2025.03.014_bib0017","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1111\/eci.12643","article-title":"Familial hypercholesterolaemia: cholesterol efflux and coronary disease","volume":"46","author":"Versmissen","year":"2016","journal-title":"Eur J Clin Invest"},{"issue":"3","key":"10.1016\/j.jacl.2025.03.014_bib0018","doi-asserted-by":"crossref","first-page":"795","DOI":"10.3233\/JAD-160551","article-title":"Altered sphingolipid balance in capillary cerebral amyloid angiopathy","volume":"60","author":"de Wit","year":"2017","journal-title":"J Alzheimers Dis"},{"issue":"8","key":"10.1016\/j.jacl.2025.03.014_bib0019","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1194\/jlr.M700113-JLR200","article-title":"An ELISA for apolipoprotein M reveals a strong correlation to total cholesterol in human plasma","volume":"48","author":"Axler","year":"2007","journal-title":"J Lipid Res"},{"issue":"4","key":"10.1016\/j.jacl.2025.03.014_bib0020","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/pst.185","article-title":"Sample size of 12 per group rule of thumb for a pilot study","volume":"4","author":"Julious","year":"2005","journal-title":"Pharm Stat"},{"issue":"1","key":"10.1016\/j.jacl.2025.03.014_bib0021","first-page":"21","article-title":"Effects of antihypertensive treatment with angiotensin II receptor blockers on lipid profile: an open multi-drug comparison trial","volume":"47","author":"Kyvelou","year":"2006","journal-title":"Hellenic J Cardiol"},{"issue":"2","key":"10.1016\/j.jacl.2025.03.014_bib0022","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.jacl.2020.01.005","article-title":"Ceramides and risk of major adverse cardiovascular events: a meta-analysis of longitudinal studies","volume":"14","author":"Mantovani","year":"2020","journal-title":"J Clin Lipidol"},{"issue":"12","key":"10.1016\/j.jacl.2025.03.014_bib0023","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0029222","article-title":"Antihypertensive treatment differentially affects vascular sphingolipid biology in spontaneously hypertensive rats","volume":"6","author":"Spijkers","year":"2011","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.jacl.2025.03.014_bib0024","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.diabet.2019.05.008","article-title":"Association between specific plasma ceramides and high-sensitivity C-reactive protein levels in postmenopausal women with type 2 diabetes","volume":"46","author":"Mantovani","year":"2020","journal-title":"Diabetes Metab"},{"issue":"5","key":"10.1016\/j.jacl.2025.03.014_bib0025","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1007\/s00125-015-3525-8","article-title":"Pathophysiology of diabetic dyslipidaemia: where are we?","volume":"58","author":"Verges","year":"2015","journal-title":"Diabetologia"},{"issue":"11","key":"10.1016\/j.jacl.2025.03.014_bib0026","doi-asserted-by":"crossref","first-page":"4222","DOI":"10.1172\/JCI57144","article-title":"Ceramides as modulators of cellular and whole-body metabolism","volume":"121","author":"Bikman","year":"2011","journal-title":"J Clin Invest"},{"issue":"23","key":"10.1016\/j.jacl.2025.03.014_bib0027","doi-asserted-by":"crossref","first-page":"9213","DOI":"10.1074\/jbc.RA118.006259","article-title":"An ANGPTL4-ceramide-protein kinase czeta axis mediates chronic glucocorticoid exposure-induced hepatic steatosis and hypertriglyceridemia in mice","volume":"294","author":"Chen","year":"2019","journal-title":"J Biol Chem"},{"issue":"3","key":"10.1016\/j.jacl.2025.03.014_bib0028","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.tem.2013.12.005","article-title":"Regulation of lipoprotein lipase by Angptl4","volume":"25","author":"Dijk","year":"2014","journal-title":"Trends Endocrinol Metab"},{"issue":"8","key":"10.1016\/j.jacl.2025.03.014_bib0029","doi-asserted-by":"crossref","first-page":"4244","DOI":"10.3390\/ijms23084244","article-title":"Implications of sphingolipid metabolites in kidney diseases","volume":"23","author":"Mallela","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.jacl.2025.03.014_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabet.2020.03.003","article-title":"Association between increased plasma ceramides and chronic kidney disease in patients with and without ischemic heart disease","volume":"47","author":"Mantovani","year":"2021","journal-title":"Diabetes Metab"},{"issue":"1","key":"10.1016\/j.jacl.2025.03.014_bib0031","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1113\/expphysiol.2014.082149","article-title":"Differential activation of receptors and signal pathways upon stimulation by different doses of sphingosine-1-phosphate in endothelial cells","volume":"100","author":"Li","year":"2015","journal-title":"Exp Physiol"},{"issue":"9","key":"10.1016\/j.jacl.2025.03.014_bib0032","article-title":"Post-translational modifications of S1PR1 and endothelial barrier regulation","volume":"1865","author":"Anwar","year":"2020","journal-title":"Biochim Biophys Acta Mol Cell Biol Lipids"},{"issue":"4","key":"10.1016\/j.jacl.2025.03.014_bib0033","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1161\/HYPERTENSIONAHA.110.162719","article-title":"Sphingosine-1-phosphate-induced inflammation involves receptor tyrosine kinase transactivation in vascular cells: upregulation in hypertension","volume":"57","author":"Yogi","year":"2011","journal-title":"Hypertension"},{"issue":"2","key":"10.1016\/j.jacl.2025.03.014_bib0034","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1093\/cvr\/cvp064","article-title":"Sphingosine-1-phosphate and modulation of vascular tone","volume":"82","author":"Igarashi","year":"2009","journal-title":"Cardiovasc Res"},{"issue":"2","key":"10.1016\/j.jacl.2025.03.014_bib0035","doi-asserted-by":"crossref","first-page":"133","DOI":"10.7326\/0003-4819-122-2-199501150-00010","article-title":"Effects of antihypertensive therapy on serum lipids","volume":"122","author":"Kasiske","year":"1995","journal-title":"Ann Intern Med"},{"issue":"4","key":"10.1016\/j.jacl.2025.03.014_bib0036","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1177\/147323000102900402","article-title":"Effect of the angiotensin II receptor antagonist valsartan on lipid profile and glucose metabolism in patients with hypertension","volume":"29","author":"Hanefeld","year":"2001","journal-title":"J Int Med Res"},{"issue":"2","key":"10.1016\/j.jacl.2025.03.014_bib0037","doi-asserted-by":"crossref","first-page":"411","DOI":"10.3390\/ijms20020411","article-title":"Ceramide and regulation of vascular tone","volume":"20","author":"Cogolludo","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"2","key":"10.1016\/j.jacl.2025.03.014_bib0038","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.biochi.2011.09.007","article-title":"Inhibitors of specific ceramide synthases","volume":"94","author":"Schiffmann","year":"2012","journal-title":"Biochimie"},{"key":"10.1016\/j.jacl.2025.03.014_bib0039","series-title":"Endotext [Internet]","article-title":"Triglyceride lowering drugs. 2024","author":"Feingold","year":"2000"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287425000674?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287425000674?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T07:33:19Z","timestamp":1750663999000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287425000674"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S1933287425000674"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2025.03.014","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Triglyceride-rich lipoprotein sphingolipids are altered in primary hypertension: A pilot case-control study","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2025.03.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 National Lipid Association. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}